Amneal Pharmaceuticals (AMRX) EBT Margin (2017 - 2026)

Amneal Pharmaceuticals' EBT Margin history runs 10 years deep, the most recent figure standing at 11.1% for Q1 2026.

• On a quarterly basis, EBT Margin rose 571.0% year-over-year to 11.1% in Q1 2026; TTM through Mar 2026 was 5.97%, a 392.0% increase from a year earlier, with the FY2025 full-year figure at 4.61%, up 658.0% from the prior year.
• EBT Margin climbed to 11.1% in Q1 2026 per AMRX's latest filing, from 6.78% in the prior quarter.
• Across five years, EBT Margin topped out at 11.1% in Q1 2026 and bottomed at 41.61% in Q2 2022.
• The 5-year median for EBT Margin is 0.48% (2022), against an average of 1.65%.
• Across the five-year window, EBT Margin sank 4812 bps in 2022 and surged 4656 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 0.48% in 2022, then plunged by 2897 bps to 13.53% in 2023, then jumped by 84 bps to 2.1% in 2024, then surged by 423 bps to 6.78% in 2025, then soared by 64 bps to 11.1% in 2026.
• Per Business Quant, the three latest AMRX EBT Margin figures stand at 11.1% (Q1 2026), 6.78% (Q4 2025), and 0.67% (Q3 2025).